ArticleSexually transmitted infections2012
Quality of life valuations of HPV-associated cancer health states by the general population.
Article in Sexually transmitted infections, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic literature review of health state utility values in head and neck cancer.Health and quality of life outcomes · 2017Pooled it
- Pooled it
- Economic evaluation of 22 HPV vaccination strategies to minimize the risk of penile, anal, and oropharyngeal cancers in Chinese males: A Markov model analysis.Human vaccines & immunotherapeutics · 2026Article
- Cost-utility of screening with liquid cytology or p16/Ki67 dual stain in women identified in cervical cancer triage with non 16/18 HR-HPV.International journal of technology assessment in health care · 2026Article
- Public Health Impact and Cost-Effectiveness of Routine and Catch-Up Human Papillomavirus Vaccination in Girls and Women in Selected Regions of China: A Model-Based Study.PharmacoEconomics · 2026Article
- Cost-effectiveness of self-sampling and enhanced strategies for HPV prevention among men who have sex with men in China: a modeling study.BMC medicine · 2025Article
- Cost-effectiveness analysis of margin-controlled surgery for vulvar Paget's disease.Gynecologic oncology reports · 2024Article
- The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023Review
- The interplay of HIV and human papillomavirus-related cancers in sub-Saharan Africa: scoping review.Systematic reviews · 2020Article
- Evidence on the prevalence, incidence, mortality and trends of human papilloma virus-associated cancers in sub-Saharan Africa: systematic scoping review.BMC cancer · 2019Article
- Cost-effectiveness analysis of anal cancer screening in women with cervical neoplasia in British Columbia, Canada.BMC health services research · 2016Article
- Cost-effectiveness of screening for anal cancer using regular digital ano-rectal examinations in men who have sex with men living with HIV.Journal of the International AIDS Society · 2016Article
- Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis.BMJ (Clinical research ed.) · 2015Article
- Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway.The Journal of infectious diseases · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo obtain health-related quality of life valuations (ie, utilities) for human papillomavirus (HPV)-related cancer health states of vulval, vaginal, penile, anal and oropharyngeal cancers for use in modelling cost-effectiveness of prophylactic HPV vaccination.
methodsWritten case descriptions of each HPV-associated cancer describing the 'average' patient surviving after the initial cancer diagnosis and treatment were developed in consultation with oncology clinicians. A general overview, standard gamble questionnaire for each health state and a quiz was conducted in 120 participants recruited from the general population.
resultsIn the included population sample (n=99), the average age was 43 years (range = 18-70 years) with 54% men, 44% never married/43% married, 76% education beyond year 12 and 39% employed full-time. The utility values for the five health states were 0.57 (95% CI 0.52 to 0.62) for anal cancer, 0.58 (0.53 to 0.63) for oropharyngeal cancer, 0.59 (0.54 to 0.64) for vaginal cancer, 0.65 (0.60 to 0.70) for vulval cancer and 0.79 (0.74 to 0.84) for penile cancer. Participants demonstrated a very good understanding of the symptoms, diagnosis and treatment of these cancers with a mean score of 9 (SD=1.1) on a 10-item quiz.
conclusionsThis study provides utility estimates for the specific HPV-related cancers of vulval, vaginal, penile, anal and oropharyngeal cancers valued by a general population sample using standard gamble. The results demonstrate considerable quality of life impact associated with surviving these cancers that will be important to incorporate into modelling cost-effectiveness of prophylactic HPV vaccination in different populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.